(Total Views: 589)
Posted On: 07/30/2020 10:26:51 AM
Post# of 149425
Also worth noting the the Lenzi study and current trial are laden with exclusion criteria.
And GM-CSF is only elevated in 20-30% of severe patients. Lenzi appears to be useful, but it's not in the same ballpark as Leronlimab.
And GM-CSF is only elevated in 20-30% of severe patients. Lenzi appears to be useful, but it's not in the same ballpark as Leronlimab.
(2)
(0)Scroll down for more posts ▼
